EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Klinische Studie (Phase III)Multizentrische StudieRandomisierte kontrollierte StudieOpen Access · CC BY 4.0

Bulevirtide Monotherapy Is Safe and Well Tolerated in Chronic Hepatitis Delta: An Integrated Safety Analysis of Bulevirtide Clinical Trials at Week 48

Tarik Asselah iD, Pietro Lampertico iD, Soo Aleman, Marc Bourlière, Adrian Streinu-Cercel, Pavel Bogomolov, Viacheslav Morozov, Tatiana Stepanova, Stefan Lazar, Dmitry Manuilov iD, Renee-Claude Mercier, Steve Tseng und 8 weitere

Liver International · 2025

DOI: 10.1111/liv.16174 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Liver International, 2025. Verfasst von Tarik Asselah und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatology, Hôpital Beaujon, Université de Paris-Cité, INSERM UMR1149, Clichy, France. Hauptthemen laut MEDLINE: Antiviral Agents, Hepatitis D, Chronic. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Gilead Sciences Inc., Gilead Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims The safety and tolerability of bulevirtide (BLV), a novel entry inhibitor of hepatitis delta virus, were evaluated in an integrated analysis of clinical trial results from patients with chronic hepatitis delta (CHD).

Methods

Week 48 on‐treatment clinical and laboratory results from two Phase 2 trials (MYR203 [NCT02888106] and MYR204 [NCT03852433]) and one Phase 3 trial (MYR301 [NCT03852719]) were pooled ( N = 269). Patients were grouped as follows: BLV 2 mg ( n = 64), BLV 10 mg ( n = 115), pegylated interferon‐alfa ( n = 39) and control ( n = 51). The control group consisted of patients assigned to the delayed treatment group in Study MYR301.

Results

Adverse events (AEs) that occurred more frequently with BLV 2 mg and BLV 10 mg versus control included increased total bile acid levels (20% and 17% vs. 0%), injection‐site reactions (16% and 20% vs. 0%), headache (16% and 17% vs. 0%), pruritus (11% and 10% vs. 0%) and eosinophilia (9% and 4% vs. 0%). Increases in total bile acid levels were observed with BLV without clear correlation with AEs, such as pruritus, eosinophilia or vitamin D deficiency. Grade 3 or 4 study drug–related AEs occurred in a higher proportion of patients receiving pegylated interferon‐alfa (51%) than with BLV 2 or 10 mg (3% and 4%, respectively). There were no serious AEs related to BLV, and no patients discontinued BLV due to an AE. Neither hepatic decompensation nor death occurred.

Conclusions

BLV monotherapy was safe and well tolerated through 48 weeks of treatment in patients with CHD. Trial Registration: NCT02888106, NCT03852433 and NCT03852719

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsHepatitis D, ChronicAdultAgedFemaleHumansMaleMiddle AgedHepatitis Delta VirusInterferon-alphaPolyethylene GlycolsRecombinant ProteinsTreatment Outcome

Stichwörter der Autor:innen

Hepcludexantiviral agentbulevirtidehepatitis B virushepatitis D virussafety

Substanzen

Antiviral AgentsInterferon-alphapeginterferon alfa-2aPolyethylene GlycolsRecombinant Proteins

Autor:innen und Institutionen

  • Department of Hepatology, Hôpital Beaujon, Université de Paris-Cité, INSERM UMR1149, Clichy, France.
  • Division of Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
  • CRC 'A. M. And A. Migliavacca' Center for Liver Disease, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.
  • Department of Infectious Diseases, Karolinska University Hospital/Karolinska Institutet, Stockholm, Sweden.
  • Hôpital Saint Joseph, Marseille, France.
  • National Institute for Infectious Diseases 'Prof. Dr. Matei Bals', Bucharest, Romania.

ORCID-Profile: Tarik Asselah, Pietro Lampertico, Dmitry Manuilov, Maurizia R Brunetto, Heiner Wedemeyer

Förderung

  • Gilead Sciences Inc.
  • Gilead Sciences

Zitieren

APA

Asselah, T., Lampertico, P., Aleman, S., Bourlière, M., Streinu-Cercel, A., Bogomolov, P., Morozov, V., Stepanova, T., Lazar, S., Manuilov, D., Mercier, R. C., Tseng, S., Ye, L., Flaherty, J. F., Osinusi, A., Da, B. L., Chee, G. M., Lau, A. H., Brunetto, M. R., & Wedemeyer, H. (2025). Bulevirtide Monotherapy Is Safe and Well Tolerated in Chronic Hepatitis Delta: An Integrated Safety Analysis of Bulevirtide Clinical Trials at Week 48. Liver International. https://doi.org/10.1111/liv.16174

Vancouver

Asselah T, Lampertico P, Aleman S, Bourlière M, Streinu-Cercel A, Bogomolov P, et al. Bulevirtide Monotherapy Is Safe and Well Tolerated in Chronic Hepatitis Delta: An Integrated Safety Analysis of Bulevirtide Clinical Trials at Week 48. Liver International. 2025. doi:10.1111/liv.16174

BibTeX
@article{Asselah2025,
  author = {Asselah, Tarik and Lampertico, Pietro and Aleman, Soo and Bourlière, Marc and Streinu-Cercel, Adrian and Bogomolov, Pavel and Morozov, Viacheslav and Stepanova, Tatiana and Lazar, Stefan and Manuilov, Dmitry and Mercier, Renee-Claude and Tseng, Steve and Ye, Lei and Flaherty, John F and Osinusi, Anu and Da, Ben L and Chee, Grace M and Lau, Audrey H and Brunetto, Maurizia R and Wedemeyer, Heiner},
  title = {Bulevirtide Monotherapy Is Safe and Well Tolerated in Chronic Hepatitis Delta: An Integrated Safety Analysis of Bulevirtide Clinical Trials at Week 48},
  journal = {Liver International},
  year = {2025},
  doi = {10.1111/liv.16174}
}
Kostenlos starten →